What We're Reading: Page 242
Industry reads hand-picked by our editors
Sep 27, 2018
-
The Wall Street Journal
Young cancer patients in poor countries get a boost
-
Bloomberg
IRS weighs easing tax-free spinoff rules in boon to tech, pharma
-
Los Angeles Blade
Big Pharma fights AHF’s rent/housing initiative
-
The New York Times
Cancer center switches focus on fund-raising as problems mount
Sep 26, 2018
-
The Wall Street Journal
High hopes for a gene therapy come with fears over cost
-
Reuters
GSK vaccine success a milestone in TB, but room for improvement
-
The New York Times
Trial by Fire: Critics Demand That a Huge Sepsis Study Be Stopped
Sep 25, 2018
-
The Times
Interview: I was right to fight off Pfizer, says Astra Zeneca boss Pascal Soriot
-
The New York Times
Drug industry tries to slip $4 billion windfall into opioid bill
-
Forbes
Paralyzed patients go from wheelchairs to walkers with experimental treatment
-
The New York Times
Congratulations. Your study went nowhere.
Sep 24, 2018
Sep 21, 2018
-
The Wall Street Journal
Drugmakers’ Free Services Spur Government Scrutiny
-
The New York Times
Sloan Kettering's Cozy Deal With Start-Up Ignites a New Uproar
-
BioCentury
FDA may crack down on clinical trial reporting
-
STAT
Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial
Sep 20, 2018
-
Bloomberg
Gilead faces doubts on Wall Street a year after $12 billion deal
-
Vox
What is Tilray? Why the Canadian cannabis company is worth more than American Airlines
-
Stat
In the battle for life sciences companies, one state shows up behind enemy lines
-
Kaiser Health News
Despite red flags at surgery centers, overseers award gold seals
Sep 19, 2018
-
ProPublica
Black Patients Miss Out On Promising Cancer Drugs
-
Reuters
AstraZeneca plots China robot offensive to counter price cuts
-
The New York Times
Why Your DNA Is Still Uncharted Territory
-
Evaluate
Novartis nears gene therapy confirmation
Previous
